Exchange: NASDAQ·Updated 06:30 PM EDT
EVMN logo

EVMNEvommune Inc

$12.45
$0.46
(3.84%)
Today
Closed $12.45
$0.28
(2.25%)
After Hours
Mkt Cap$431.86M
Vol861,584.00
News
all
press releases
Evommune Becomes Oversold (EVMN)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, July 7, 2026 Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous...
PR Newswire
News Placeholder
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) PR Newswire NEW YORK, June 30, 2026 Evommune's CEO and...
PR Newswire
News Placeholder
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
Zacks
News Placeholder
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp, and Evommune. See analyst ratings for these stocks.read more...
Benzinga
News Placeholder
Evommune's Skin Disorder Study Falls Short
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.read more...
Benzinga
News Placeholder
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial...
Business Wire
News Placeholder
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced...
Business Wire
News Placeholder
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell
Wall Street Zen downgraded Evommune from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
News Placeholder
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus
Stifel Nicolaus began coverage on shares of Evommune in a report on Friday. They set a "buy" rating and a $54.00 target price on the stock...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.